Chinese Biopharmaceutical Industry: Current State and Future Development

The development of biologic drugs has gradually become the key focus of all drug companies worldwide, large or small, major or startup. Major pharma companies, which used to almost exclusively focus on small molecule drugs, are now paying more attention to biologics. Growing numbers of small biopharma companies also focus on discovery and development of novel biologic drugs or niche technologies which are increasingly licensed in by major biopharma companies.

Meanwhile, therapeutic biologics are gaining increasing acceptance among patients and thus become a new but important type of medication. An increasing number of biologic drugs have become new blockbusters. The global market value of biologic drugs has thus been growing much faster than the traditional small molecule drugs. Moreover, it has been poised to continue to grow in even a faster pace in the foreseeable future.

Although starting relatively late, biopharma industry in China has also been experiencing fast development in the recent decade. The improvement of the industrial infrastructure through the investment of a significant amount of capitals by Chinese government at various levels, the influx of a large number of returnees, increasingly readily available funding from various sources and the entrance of a growing number of experienced multinational companies all have contributed to the fast growth of the biopharma industry in China.

The Chinese biopharma industry has thus received growing attention. The capability of the Chinese biopharma industry in R&D and manufacturing, the quality of Chinese-made biologic products and the service capability of Chinese bio-CROs and bio-CMOs, all have become increasingly important to and concerned by biopharma companies around the world.

The report, “Chinese Biopharmaceutical Industry: Current State and Future Development”, analyzed in detail the Chinese biopharma industry in all aspects including its current capability and capacity in R&D, manufacturing and outsourcing service. With the in-depth analysis of its current strengths and weakness, the report provides clear insights into the current development state of this Chinese industry including where it currently stands in the global landscape of the same industry. Moreover, the report also analyzed in depth the future growth drivers and resistors of the Chinese industry and how they would likely affect its future development.

The report is a must-read book to global pharma and biopharma companies that are seeking marketing opportunities in China and collaboration with Chinese biopharma companies, venture capital investors interested in investment opportunities in the Chinese biopharma industry, market research/consultancy companies seeking the information of the development of Chinese biopharma industry, and even the government agencies of those countries that are interested in learning the current and future development of Chinese biopharma industry.